000095314 001__ 95314
000095314 005__ 20210902121824.0
000095314 0247_ $$2doi$$a10.3390/cells9061525
000095314 0248_ $$2sideral$$a119056
000095314 037__ $$aART-2020-119056
000095314 041__ $$aeng
000095314 100__ $$aGascon, Marta
000095314 245__ $$aIntratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?
000095314 260__ $$c2020
000095314 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095314 5203_ $$aThe molecular and cell determinants that modulate immune checkpoint (ICI) efficacy in lung cancer are still not well understood. However, there is a necessity to select those patients that will most benefit from these new treatments. Recent studies suggest the presence and/or the relative balance of specific lymphoid cells in the tumor microenvironment (TEM) including the T cell (activated, memory, and regulatory) and NK cell (CD56dim/bright) subsets, and correlate with a better response to ICI. The analyses of these cell subsets in peripheral blood, as a more accessible and homogeneous sample, might facilitate clinical decisions concerning fast prediction of ICI efficacy. Despite recent studies suggesting that lymphoid circulating cells might correlate with ICI efficacy and toxicity, more analyses and investigation are required to confirm if circulating lymphoid cells are a relevant picture of the lung TME and could be instrumental as ICI response biomarkers. This short review is aimed to discuss the recent advances in this fast-growing field.
000095314 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B29$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2017-83120-C2-1-R
000095314 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095314 590__ $$a6.6$$b2020
000095314 591__ $$aCELL BIOLOGY$$b53 / 195 = 0.272$$c2020$$dQ2$$eT1
000095314 592__ $$a1.22$$b2020
000095314 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1
000095314 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000095314 700__ $$aIsla, Dolores
000095314 700__ $$aCruellas, Mara
000095314 700__ $$aGalvez, Eva M.
000095314 700__ $$aLastra, Rodrigo
000095314 700__ $$aOcariz, Maitane
000095314 700__ $$0(orcid)0000-0002-9600-8116$$aPaño, José Ramón$$uUniversidad de Zaragoza
000095314 700__ $$aRamirez, Ariel
000095314 700__ $$aSesma, Andrea
000095314 700__ $$0(orcid)0000-0003-3387-0558$$aTorres-Ramón, Irene$$uUniversidad de Zaragoza
000095314 700__ $$aYubero, Alfonso
000095314 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000095314 700__ $$0(orcid)0000-0003-3043-147X$$aMartinez-Lostao, Luis$$uUniversidad de Zaragoza
000095314 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000095314 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000095314 773__ $$g9, 6 (2020), 1525 [16 pp.]$$pCells$$tCELLS$$x2073-4409
000095314 8564_ $$s818240$$uhttps://zaguan.unizar.es/record/95314/files/texto_completo.pdf$$yVersión publicada
000095314 8564_ $$s456844$$uhttps://zaguan.unizar.es/record/95314/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095314 909CO $$ooai:zaguan.unizar.es:95314$$particulos$$pdriver
000095314 951__ $$a2021-09-02-10:10:55
000095314 980__ $$aARTICLE